Vertex announces fda approval of journavx™ (suzetrigine), a first-in-class treatment for adults with moderate-to-severe acute pain

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the u.s. food and drug administration (fda) has approved journavx™ (suzetrigine), an oral, non-opioid, highly selective nav1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. journavx is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. “today's approval is a histori.
VRTX Ratings Summary
VRTX Quant Ranking